Table 2.
Stratified analysis comparing transarterial chemoembolization treatment in barcelona clinic liver cancer stage B
| Variable | BCLC stage B overall (n = 135) | BCLC stage B with TACE (n = 77) | BCLC stage B without TACE (n = 58) | P value |
| Age, yr (± SD) | 65 ± 10 | 65 ± 8 | 65 ± 11 | 0.86 |
| Male gender, n (%) | 111 (82.2) | 68 (88.3) | 43 (74.1) | 0.03 |
| Non-cirrhotic liver, n (%) | 23 (17.0) | 7 (9.1) | 16 (27.6) | 0.006 |
| Etiology, n (%) | 0.11 | |||
| HCV | 42 (31.1) | 25 (32.5) | 17 (29.3) | |
| HBV | 8 (5.9) | 5 (6.5) | 3 (5.2) | |
| Alcohol | 29 (21.5) | 21 (27.3) | 8 (13.8) | |
| Etiology, nNASH | 14 (10.4) | 6 (7.8) | 8 (13.8) | |
| Etiology, nOthers | 42 (31.1) | 20 (25.9) | 22 (37.9) | |
| Child Pugh A/B, n (%) | 88 (65.2)/47 (34.8) | 48 (62.3)/29 (37.7) | 40 (69.0)/18 (31.0) | 0.42 |
| CSPH1, n (%) | 67 (49.6) | 45 (58.4) | 22 (37.9) | 0.018 |
| Median nº HCC nodules (IQR) | 2 (2-3) | 2 (1-3) | 2 (1-4) | 0.39 |
| Median largest HCC diameter, mm, (IQR) | 65 (43-100) | 60 (43-88) | 69.5 (45-114.5) | 0.11 |
| Bilobar involvement, n (%) | 53 (39.3) | 30 (39.0) | 23 (39.7) | 0.72 |
| Diffuse HCC pattern, n (%) | 5 (3.7) | 2 (2.6) | 3 (5.2) | 0.72 |
| Median AFP, ng/mL (IQR) | 26.7 (4.7-248.5) | 27.5 (5.1-202.85) | 24.4 (4.3-285) | 0.91 |
| AFP > 200 ng/mL, n (%) | 36 (27.3) | 19 (25.0) | 17 (30.4) | 0.49 |
| AFP > 400 ng/mL, n (%) | 30 (22.7) | 17 (22.4) | 13 (23.2) | 0.91 |
| AFP > 1000 ng/mL, n (%) | 18 (13.6) | 11 (14.5) | 7 (12.5) | 0.74 |
| Vascular invasion, n (%) | - | |||
| Extrahepatic disease, n (%) | - |
1
Clinically significant portal hypertension defined as presence of at least one of the following: Ascites, gastro-aesophagueal varices or hepatic encephalopathy. AFP: Alpha-feto protein; TACE: Transarterial chemoembolization; BCLC: Barcelona clinic liver cancer.